Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Trial of Encapsulated Rapamycin (eRapa) in Prostate Cancer Patients Under Active Surveillance

Trial Profile

Phase Ib Trial of Encapsulated Rapamycin (eRapa) in Prostate Cancer Patients Under Active Surveillance

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2018

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Sep 2018 According to a Rapamycin Holdings media release, dosing has been initiated and first patient has been treated in the trial. The company expects to conclude the trial sometime in mid-2019.
    • 16 Aug 2018 New trial record
    • 14 Aug 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top